|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn849940856 |
003 |
OCoLC |
005 |
20231117044906.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
130611s2013 ne a ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d OCLCF
|d OCLCO
|d EBLCP
|d YDXCP
|d OPELS
|d UKDOC
|d DEBSZ
|d OCLCQ
|d DEBBG
|d D6H
|d OCLCE
|d UKBTH
|d OCLCQ
|d SFB
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 851315817
|a 1084726866
|a 1127137787
|
020 |
|
|
|a 0124078028
|
020 |
|
|
|a 9780124078024
|
035 |
|
|
|a (OCoLC)849940856
|z (OCoLC)851315817
|z (OCoLC)1084726866
|z (OCoLC)1127137787
|
050 |
|
4 |
|a QH430
|b .A38 2013eb
|
082 |
0 |
4 |
|a 575.5
|2 23
|
245 |
0 |
0 |
|a Advances in genetics
|n Volume 82 /
|c edited by Theodore Friedmann, Jay C. Dunlap, Stephen Goodwin.
|
260 |
|
|
|a Amsterdam, Netherlands :
|b Elsevier,
|c �2013.
|
300 |
|
|
|a 1 online resource (vii, 111 pages) :
|b illustrations (some color)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
588 |
0 |
|
|a Online resource; title from title page (ebrary, viewed June 11, 2013).
|
505 |
0 |
|
|a Front Cover; Advances in Genetics; Copyright; Contents; Contributors; Chapter One: The Repair and Signaling Responses to DNA Double-Strand Breaks; 1. Introduction; 2. Formation of DSBs; 3. Mechanisms of DSB Rejoining; 3.1. Homologous recombination; 3.2. Nonhomologous end-joining; 3.2.1. DNA-PK: The first complex formed during NHEJ; 3.2.2. DSB end processing during NHEJ; 3.2.3. DNA ligase IV, XRCC4, and XLF, the second NHEJ complex; 3.3. Additional end-joining processes; 4. DNA Damage Response Signaling; 4.1. The assembly process; 4.2. Factors regulating the recruitment of 53BP1
|
505 |
8 |
|
|a 4.3. Assembly of the BRCA1 and the RAP80/Abraxas/BRCC36 complex4.4. Involvement of noncoding RNAs; 5. Functions of the DDR Assembly; 5.1. Signaling to the checkpoint machinery; 5.2. The repair of DSB located within heterochromatin; 5.3. Transcriptional arrest at transcriptionally active DSBs; 5.4. Impact of additional chromatin changes at DSBs; 5.4.1. Role for HP1 in the DDR; 5.4.2. The involvement of CHD4-NuRD in the DDR; 5.4.3. The involvement of Tip60 and the NuA4 complex in the DDR; 5.4.4. The involvement of SNF2H, ACF1, and RNF20-RNF40 in the DDR
|
505 |
8 |
|
|a 6. Regulation of DSB Repair Pathway Choice6.1. Impact of cell cycle phase and resection; 6.2. Role of 53BP1; 6.3. Model for the interface between NHEJ and HR; 7. Contribution of Defects in DSB Rejoining Processes to Human Disease; 8. Concluding Remarks; References; Chapter Two: Biological Activity and Biotechnological Aspects of Locked Nucleic Acids; 1. Brief Introduction; 2. Chemistry and Structure; 2.1. LNA characteristics and structure; 2.2. LNA analogues and conjugates; 3. Biological Activity of LNA-Containing ONs; 3.1. Antisense LNA; 3.1.1. Affinity and potency
|
505 |
8 |
|
|a 3.1.2. Cellular uptake and gymnosis3.1.2.1. Uptake mechanisms; 3.1.2.2. Comparing cellular uptake and antisense efficiency; 3.2. siLNA: Improving siRNA performance by LNA modification; 3.2.1. Tolerance for LNA modification; 3.2.2. Enhancing siRNA activity and specificity by LNA modification; 3.2.3. Enhancing siRNA nuclease resistance by LNA modification; 3.2.4. Reducing siRNA immunogenicity by LNA modification; 3.2.5. Applying siLNA in vivo; 3.3. LNA and splice-switching ONs; 3.3.1. Splice switching; 3.3.2. LNA in SSOs; 3.4. LNA in antigene reagents; 3.4.1. LNA in triplex-forming ONs
|
505 |
8 |
|
|a 3.4.1.1. LNA-modified pyrimidine TFOs3.4.1.2. Intracellular effects of LNA-modified pyrimidine TFOs; 3.4.2. LNA in double-strand-invading ONs; 3.4.2.1. LNA-containing clamp ONs; 3.4.2.2. Invader-LNA; 3.4.2.3. Zorro-LNA; 3.4.2.4. ``Linear� � antigene LNA ONs; 4. LNA Pharmacology; 4.1. Pharmacokinetics; 4.1.1. Delivery and bioavailability; 4.1.2. Tissue distribution; 4.2. Pharmacodynamics; 4.2.1. Targeting ApoB-100; 4.2.2. Targeting PCSK9; 4.2.3. Targeting miR-122; 4.2.4. LNA pharmacology in malignant tissues; 5. LNA in Biotechnology; 5.1. LNA in primers and probes; 5.1.1. LNA primers
|
520 |
|
|
|a The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines. * Includes methods for testing with ethical, legal, and social implications* Critically analyzes future.
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Genetics.
|
650 |
|
6 |
|a G�en�etique.
|0 (CaQQLa)201-0069234
|
650 |
|
7 |
|a genetics.
|2 aat
|0 (CStmoGRI)aat300138822
|
650 |
|
7 |
|a Genetics
|2 fast
|0 (OCoLC)fst00940117
|
700 |
1 |
|
|a Friedmann, Theodore.
|
700 |
1 |
|
|a Dunlap, Jay C.
|
700 |
1 |
|
|a Goodwin, Stephen.
|
776 |
0 |
8 |
|i Online version:
|t Advances in genetics Volume 82.
|d Amsterdam, Netherlands : Elsevier, �2013
|w (OCoLC)1084726866
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780124076761
|z Texto completo
|